Piotr Lewczuk

List of Publications by Year
in descending order

105 papers	9,350 citations	71004 43 h-index	45040 94 g-index
109 all docs	109 docs citations	109 times ranked	10573 citing authors

#	Article	IF	Citations
1	Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment—data from the Dementia Competence Network. Journal of Neural Transmission, 2022, 129, 477-486.	1.4	14
2	Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer's type. Brain, 2022, 145, 2507-2517.	3.7	16
3	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.4	26
4	Cholesterol metabolites and plant sterols in cerebrospinal fluid are associated with Alzheimer's cerebral pathology and clinical disease progression. Journal of Steroid Biochemistry and Molecular Biology, 2021, 205, 105785.	1.2	19
5	A comment on the paper 'Biomarkers in Multiple Sclerosis' by Sapko et al.. Neurologia I Neurochirurgia Polska, 2021, 55, 115-116.	0.6	0
6	Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression. Alzheimer's Research and Therapy, 2021, 13, 65.	3.0	49
7	Cerebrospinal fluid α synuclein concentrations in patients with positive AD biomarkers and extrapyramidal symptoms. Journal of Neural Transmission, 2021, 128, 817-825.	1.4	2
8	Nephelometry and Turbidimetry: Methods to Quantify Albumin and Immunoglobulins Concentrations in Clinical Neurochemistry. Neuromethods, 2021, , 17-27.	0.2	0
9	IL-6 Quotient (The Ratio of Cerebrospinal Fluid IL-6 to Serum IL-6) as a Biomarker of an Unruptured Intracranial Aneurysm. Journal of Inflammation Research, 2021, Volume 14, 6103-6114.	1.6	12
10	Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory. Diagnostics, 2021, 11, 2372.	1.3	7
11	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2021, 17, .	0.4	7
12	First amyloid β1‑42 certified reference material for re‑calibrating commercial immunoassays. Alzheimer's and Dementia, 2020, 16, 1493-1503.	0.4	42
13	Clinical significance of fluid biomarkers in Alzheimer's Disease. Pharmacological Reports, 2020, 72, 528-542.	1.5	22
14	Cardiac Surgery is Associated with Biomarker Evidence of Neuronal Damage. Journal of Alzheimer's Disease, 2020, 74, 1211-1220.	1.2	22
15	The Role of Cathepsin B in the Degradation of Aβ and in the Production of Aβ Peptides Starting With Ala2 in Cultured Astrocytes. Frontiers in Molecular Neuroscience, 2020, 13, 615740.	1.4	19
16	Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 67, 481-488.	1.2	171
17	Microvesicles from cerebrospinal fluid of patients with Alzheimer's disease display reduced concentrations of tau and APP protein. Scientific Reports, 2019, 9, 7089.	1.6	30
18	Erlangen Score Predicts Cognitive and Neuroimaging Progression in Mild Cognitive Impairment Stage of Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 69, 551-559.	1.2	6

#	Article	IF	Citations
19	Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease. Alzheimer's Research and Therapy, 2019, 11, 34.	3.0	325
20	Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects. Journal of Alzheimer's Disease, 2019, 68, 1151-1159.	1.2	9
21	Guidelines for the standardized collection of blood-based biomarkers in psychiatry: Steps for laboratory validity – a consensus of the Biomarkers Task Force from the WFSBP. World Journal of Biological Psychiatry, 2019, 20, 340-351.	1.3	20
22	Digit ratio (2D:4D) and academic success as measured by achievement in the academic degree "Habilitation". PLoS ONE, 2019, 14, e0212167.	1.1	6
23	Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 740-746.	0.9	23
24	Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 2.	3.0	19
25	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. Alzheimer's Research and Therapy, 2018, 10, 30.	3.0	40
26	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
27	Amyloid β oligomers (AβOs) in Alzheimer's disease. Journal of Neural Transmission, 2018, 125, 177-191.	1.4	114
28	Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 87.	3.0	13
29	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. Alzheimer's and Dementia, 2018, 14, 1313-1333.	0.4	87
30	Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 71.	3.0	216
31	A Specific Reduction in Aβ1−42 vs. a Universal Loss of Aβ Peptides in CSF Differentiates Alzheimer's Disease From Meningitis and Multiple Sclerosis. Frontiers in Aging Neuroscience, 2018, 10, 152.	1.7	18
32	Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer's Disease. International Journal of Molecular Sciences, 2018, 19, 1884.	1.8	66
33	CSF nonphosphorylated Tau as a biomarker for the discrimination of <scp>AD</scp> from <scp>CJD</scp>. Annals of Clinical and Translational Neurology, 2018, 5, 883-887.	1.7	17
34	CSF Aβ1−42 – an excellent but complicated Alzheimer's biomarker – a route to standardisation. Clinica Chimica Acta, 2017, 467, 27-33.	0.5	104
35	Excessive daytime sleepiness in a patient with coexisting myotonic dystrophy type 1, myasthenia gravis and Graves' disease. Neurologia I Neurochirurgia Polska, 2017, 51, 190-193.	0.6	2
36	Blood‐based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimer's and Dementia, 2017, 13, 45-58.	0.4	227

#	Article	IF	Citations
37	[P3–197]: OLIGOMERIC Aβ IN THE CEREBROSPINAL FLUID OF PATIENTS WITH EARLY ALZHEIMER's DISEASE: A PILOT STUDY. Alzheimer's and Dementia, 2017, 13, P1010.	0.4	0
38	[P4–139]: APPLICATION OF THE 'A/T/N' BIOMARKER CLASSIFICATION SYSTEM IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: CONVERSION RATES TO AD AND OTHER DEMENTIAS. Alzheimer's and Dementia, 2017, 13, P1310.	0.4	0
39	Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. Alzheimer's Research and Therapy, 2017, 9, 84.	3.0	58
40	Do we still need positron emission tomography for early Alzheimer's disease diagnosis?. Brain, 2016, 139, e60-e60.	3.7	4
41	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. Journal of Alzheimer's Disease, 2016, 55, 159-170.	1.2	23
42	Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 55, 813-822.	1.2	191
43	Homocysteine metabolism is associated with cerebrospinal fluid levels of soluble amyloid precursor protein and amyloid beta. Journal of Neurochemistry, 2016, 139, 324-332.	2.1	24
44	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. Journal of Alzheimer's Disease, 2016, 52, 51-64.	1.2	18
45	Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1177-1191.	1.4	49
46	Surface Trafficking of <scp>APP</scp> and <scp>BACE</scp> in Live Cells. Traffic, 2015, 16, 655-675.	1.3	9
47	Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects. Journal of Alzheimer's Disease, 2015, 48, 433-441.	1.2	41
48	Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease. Alzheimer's Research and Therapy, 2015, 7, 74.	3.0	109
49	A Practical Guide to Immunoassay Method Validation. Frontiers in Neurology, 2015, 6, 179.	1.1	348
50	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology, 2015, 6, 216.	1.1	36
51	Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type. Neurobiology of Aging, 2015, 36, 601-607.	1.5	125
52	Biomarkers of Alzheimer's disease and mild cognitive impairment: A current perspective. Advances in Medical Sciences, 2015, 60, 76-82.	0.9	56
53	Application of multiplexing technology to the analysis of the intrathecally released immunoglobulins against B. burgdorferi antigens in neuroborreliosis. Immunology Letters, 2015, 168, 58-63.	1.1	2
54	Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls. Alzheimer's Research and Therapy, 2015, 7, 40.	3.0	104

#	Article	IF	Citations
55	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nature Reviews Neurology, 2015, 11, 41-55.	4.9	144
56	Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 58-69.	0.4	352
57	Astrocytes and microglia but not neurons preferentially generate N-terminally truncated $A\beta$ peptides. Neurobiology of Disease, 2015, 73, 24-35.	2.1	52
58	Currently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer's Disease and Mild Cognitive Impairment. Advances in Geriatrics, 2014, 2014, 1-15.	1.6	2
59	Ventricular and Lumbar Cerebrospinal Fluid Concentrations of Alzheimer's Disease Biomarkers in Patients with Normal Pressure Hydrocephalus and Posttraumatic Hydrocephalus. Journal of Alzheimer's Disease, 2014, 41, 1057-1062.	1.2	33
60	SUCLG2 identified as both a determinator of CSF $A\beta1$–42 levels and an attenuator of cognitive decline in Alzheimer's disease. Human Molecular Genetics, 2014, 23, 6644-6658.	1.4	45
61	Concentrations of Matrix Metalloproteinases and their Tissue Inhibitors in the Cerebrospinal Fluid of Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 40, 351-357.	1.2	42
62	Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in the tumors of central nervous system (CNS). Journal of Neural Transmission, 2014, 121, 469-477.	1.4	9
63	Evaluation of Visinin-Like Protein 1 Concentrations in the Cerebrospinal Fluid of Patients with Mild Cognitive Impairment as a Dynamic Biomarker of Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 1031-1037.	1.2	33
64	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimer's and Dementia, 2014, 10, 808-817.	0.4	163
65	Amyloid-β 42/40 Cerebrospinal Fluid Concentration Ratio in the Diagnostics of Alzheimer's Disease: Validation of Two Novel Assays. Journal of Alzheimer's Disease, 2014, 43, 183-191.	1.2	149
66	P4-047: EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE WITH THE β-AMYLOID 42/40 CSF CONCENTRATION RATIO: ANALYTICAL AND CLINICAL VALIDATION OF TWO NOVEL ASSAYS. , 2014, 10, P799-P800.		1
67	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344
68	Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimer's and Dementia, 2013, 9, 137-140.	0.4	105
69	The influence of insulin infusion on the metabolism of amyloid β peptides in plasma. , 2013, 9, 400-405.		16
70	Characterization of Acid Sphingomyelinase Activity in Human Cerebrospinal Fluid. PLoS ONE, 2013, 8, e62912.	1.1	29
71	Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer's disease. Journal of Neurochemistry, 2012, 123, 310-316.	2.1	66
72	Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimer's and Dementia, 2012, 8, 65-73.	0.4	271

#	Article	IF	Citations
73	Multiplexing analysis of the polyspecific intrathecal immune response in multiple sclerosis. Methods, 2012, 56, 528-531.	1.9	10
74	The pros and cons of multiplexing: A guest-editor's introduction. Methods, 2012, 56, 461-463.	1.9	7
75	Neurochemical dementia diagnostics for Alzheimer's disease and other dementias: an ISO 15189 perspective. Biomarkers in Medicine, 2012, 6, 685-690.	0.6	5
76	Cerebrospinal Fluid Soluble Amyloid-β Protein Precursor as a Potential Novel Biomarkers of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 28, 119-125.	1.2	42
77	Multidimensional plasma protein separation technique for identification of potential Alzheimer's disease plasma biomarkers: a pilot study. Journal of Neural Transmission, 2012, 119, 779-788.	1.4	39
78	CSF markers in amyotrophic lateral sclerosis. Journal of Neural Transmission, 2012, 119, 747-757.	1.4	55
79	Increased concentration of the CSF Tau protein and its phosphorylated form in the late juvenile metachromatic leukodystrophy form: a case report. Journal of Neural Transmission, 2012, 119, 759-762.	1.4	4
80	Biomarkers of neurodegeneration – not only Alzheimer's disease and not only cerebrospinal fluid: a guest-editor's introduction. Journal of Neural Transmission, 2012, 119, 735-737.	1.4	0
81	Neurochemical dementia diagnostics in Alzheimer's disease: where are we now and where are we going?. Expert Review of Proteomics, 2011, 8, 447-458.	1.3	27
82	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.4	354
83	Preanalytical Sample Handling and Sample Stability Testing for the Neurochemical Dementia Diagnostics. Journal of Alzheimer's Disease, 2011, 25, 739-745.	1.2	50
84	Nuclear Medicine Diagnostic Techniques in the Era of Pathophysiology-Based CSF Biomarkers for Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 26, 97-103.	1.2	10
85	Association of N-Acetylaspartate and Cerebrospinal Fluid Aβ42 in Dementia. Journal of Alzheimer's Disease, 2011, 27, 393-399.	1.2	10
86	Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathologica, 2011, 121, 597-609.	3.9	256
87	Cerebrospinal fluid under non-steady state condition caused by plasmapheresis. Journal of Neural Transmission, 2011, 118, 219-222.	1.4	4
88	Cerebrospinal Fluid Tau, p-Tau 181 and Amyloid-$\beta_{38/40/42}$ in Frontotemporal Dementias and Primary Progressive Aphasias. Dementia and Geriatric Cognitive Disorders, 2011, 31, 37-44.	0.7	46
89	Confirmation rate of blinded 99mTc-SPECT compared to neurochemical dementia biomarkers in CSF in patients with Alzheimer disease. Journal of Neural Transmission, 2010, 117, 1111-1114.	1.4	6
90	Perfusion Imaging with SPECT in the Era of Pathophysiology-Based Biomarkers for Alzheimer's Disease. International Journal of Alzheimer's Disease, 2010, 2010, 1-5.	1.1	5

#	Article	IF	Citations
91	Cerebrospinal Fluid Markers for Alzheimer's Disease over the Lifespan: Effects of Age and the APOEε4 Genotype. Journal of Alzheimer's Disease, 2010, 22, 459-468.	1.2	35
92	Proinflammatory Cytokines Are Involved in the Initiation of the Abnormal Matrix Process in Pseudoexfoliation Syndrome/Glaucoma. American Journal of Pathology, 2010, 176, 2868-2879.	1.9	135
93	Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Annals of Neurology, 2009, 65, 403-413.	2.8	1,803
94	Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer's disease. Journal of Neural Transmission, 2009, 116, 203-212.	1.4	124
95	Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers. Journal of Neural Transmission, 2009, 116, 1163-1167.	1.4	80
96	Neurochemical dementia diagnostics: State of the art and research perspectives. Proteomics, 2008, 8, 1292-1301.	1.3	57
97	Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. Neurobiology of Aging, 2008, 29, 812-818.	1.5	94
98	Adherence-dependent shifts in the patterns of β-amyloid peptides secreted by human mononuclear phagocytes. Brain, Behavior, and Immunity, 2008, 22, 1044-1048.	2.0	13
99	Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho-Tau in patients with low- and high-CSF Aβ40 load. Journal of Neurochemistry, 2007, 101, 1053-1059.	2.1	237
100	International quality control survey of neurochemical dementia diagnostics. Neuroscience Letters, 2006, 409, 1-4.	1.0	102
101	Effect of Sample Collection Tubes on Cerebrospinal Fluid Concentrations of Tau Proteins and Amyloid β Peptides. Clinical Chemistry, 2006, 52, 332-334.	1.5	139
102	Tau Protein Phosphorylated at Threonine 181 in CSF as a Neurochemical Biomarker in Alzheimer's Disease: Original Data and Review of the Literature. Journal of Molecular Neuroscience, 2004, 23, 115-122.	1.1	97
103	Amyloid β peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. Biological Psychiatry, 2004, 55, 524-530.	0.7	86
104	Neurochemical diagnosis of Alzheimer's dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau. Neurobiology of Aging, 2004, 25, 273-281.	1.5	267
105	The amyloid-β (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Aβ peptide. Rapid Communications in Mass Spectrometry, 2003, 17, 1291-1296.	0.7	106